|
Stock Warrants (Narrative) (Details) (USD $)
|
9 Months Ended | 1 Months Ended | 9 Months Ended | 1 Months Ended | 1 Months Ended | 9 Months Ended | 1 Months Ended | 9 Months Ended | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2013
|
Sep. 30, 2012
|
Dec. 31, 2012
|
Sep. 30, 2013
Minimum [Member]
|
Sep. 30, 2013
Maximum [Member]
|
Sep. 30, 2013
Weighted Average [Member]
|
Jun. 30, 2013
Series HH Warrants [Member]
|
Jun. 30, 2013
Five Year Series II Warrants [Member]
|
Jun. 30, 2013
Five Year Series II Warrants [Member]
Maximum [Member]
|
Sep. 30, 2013
Three Year Series JJ Warrants [Member]
|
Sep. 30, 2013
Three Year Series JJ Warrants [Member]
Minimum [Member]
|
Sep. 30, 2013
Three Year Series JJ Warrants [Member]
Maximum [Member]
|
Jun. 30, 2013
General Electric Capital Corporation [Member]
Series HH Warrants [Member]
|
Jun. 25, 2013
General Electric Capital Corporation [Member]
Series HH Warrants [Member]
|
Sep. 30, 2013
Platinum Montaur Life Sciences, LLC Credit Facility [Member]
|
Mar. 31, 2013
Platinum Montaur Life Sciences, LLC Credit Facility [Member]
Series X Warrants [Member]
|
Sep. 30, 2013
Platinum Montaur Life Sciences, LLC Credit Facility [Member]
Series X Warrants and Series AA Warrants [Member]
|
Jun. 30, 2013
Platinum Montaur Life Sciences, LLC Credit Facility [Member]
Series X Warrants and Series AA Warrants [Member]
|
Jun. 30, 2013
Preferred Stock [Member]
|
Sep. 30, 2013
Preferred Stock [Member]
|
Jun. 30, 2013
Common Stock [Member]
|
Sep. 30, 2013
Common Stock [Member]
|
|
| Class of Warrant or Right [Line Items] | ||||||||||||||||||||||
| Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised | 3,000,000 | |||||||||||||||||||||
| Issued stock upon exercise of warrants, shares | 3,000,000 | |||||||||||||||||||||
| Proceeds from warrant exercises | $ 1,380,000 | |||||||||||||||||||||
| Series B preferred stock issued, shares | 2,364.9 | 2,364.9 | ||||||||||||||||||||
| Number of common shares underlying Series B Preferred Stock | 7,733,223 | 7,733,223 | ||||||||||||||||||||
| Shares conversion, number of common stock equivalent to each preferred stock | 3,270 | 3,270 | ||||||||||||||||||||
| Principal payments on notes payable | 5,982,156 | 620,480 | 4,781,333 | |||||||||||||||||||
| Warrants outstanding | 4,542,764 | |||||||||||||||||||||
| Exercise price of warrant issued | 1.97 | 3.83 | 3.39 | 3.04 | 3.83 | 2.00 | 3.83 | 2.49 | 2.49 | |||||||||||||
| Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 301,205 | 275,000 | 3,169,015 | 2,100,000 | 3,800,000 | 301,205 | ||||||||||||||||
| Five Year II Warrants | 5 years | |||||||||||||||||||||
| Derivative liabilities related to warrants | $ 7,675,446 | $ 0 | ||||||||||||||||||||